These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18460658)

  • 1. New limits advised for anemia drugs.
    Mitka M
    JAMA; 2008 May; 299(17):2016. PubMed ID: 18460658
    [No Abstract]   [Full Text] [Related]  

  • 2. New limits advised for anemia drugs.
    Mitka M
    JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA panel scrutinizes safety of anti-anemia drugs.
    Randal J
    J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
    [No Abstract]   [Full Text] [Related]  

  • 4. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 5. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 7. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 8. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 10. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety concerns for two big anemia drugs.
    Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer- and treatment-related anemia.
    Rodgers GM; Cella D; Chanan-Khan A; Chesney C; Cleeland C; Coccia PF; Demetri GD; Djulbegovic B; Garst JL; Gore M; Kraut EH; Lin WC; Millenson M; Mock V; Reinke D; Rosenthal J; Sabbatini P
    J Natl Compr Canc Netw; 2005 Nov; 3(6):772-89. PubMed ID: 16316613
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythropoietin-stimulating agents: new data yield new insights.
    Zitella L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
    [No Abstract]   [Full Text] [Related]  

  • 14. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 15. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 16. Peginesatide (Omontys) for anemia in chronic kidney failure.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):45-6. PubMed ID: 22683926
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Kara O; Dizdar O; Altundag K
    JAMA; 2008 Dec; 300(24):2855; author reply 2855-7. PubMed ID: 19109113
    [No Abstract]   [Full Text] [Related]  

  • 20. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.
    Glaspy JA
    Oncology (Williston Park); 2011 Apr; 25(5):423-4. PubMed ID: 21710839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.